Outlook Therapeutics Inc SEC Filings

Outlook Therapeutics filed an 8-K after completing a Federal Dispute Resolution meeting with the FDA’s Office of New Drugs regarding ONS-5010/LYTENAVA, its investigational bevacizumab formulation for wet age-related macular degeneration in the United States. The company expects a formal FDA decision from this dispute process in May 2026 and plans to update the market after receiving the agency’s response.

LYTENAVA already holds centralized Marketing Authorization in the European Union and separate authorization in the UK for wet AMD, and commercial launch has begun in Germany and the UK. In the United States, the product remains investigational following a December 30, 2025 Complete Response Letter on its biologics license application.

Outlook Therapeutics filed a report describing a key regulatory step for its retina drug candidate ONS-5010/LYTENAVA™ (bevacizumab‑vikg) in the United States. After receiving a Complete Response Letter from the FDA on December 30, 2025 for its Biologics License Application in neovascular age‑related macular degeneration, the company submitted a formal dispute resolution request. The FDA has accepted this request and granted a meeting with the deciding official in April 2026, giving the company an opportunity to argue that Phase 3 NORSE TWO and additional NORSE EIGHT data sufficiently support approval. The company notes that no safety concerns have been raised by the FDA and highlights that LYTENAVA already holds Marketing Authorizations in the EU and UK for wet AMD, where commercial launch has begun.

Outlook Therapeutics completed a best-efforts public offering of common stock and warrants. The company sold 20,000,000 shares of common stock with accompanying warrants to purchase up to 20,000,000 shares at a combined public price of $0.25 per share-and-warrant.

Gross proceeds were approximately $5.0 million, with net proceeds of about $4.0 million after placement agent fees and expenses. The investor warrants are exercisable immediately at $0.25 per share and expire five years from issuance, subject to 4.99% or 9.99% beneficial ownership caps.

H.C. Wainwright & Co. received cash fees and 1,400,000 placement agent warrants exercisable at $0.3125 per share, also for five years. The company agreed to certain lock-up and no variable-rate issuance covenants, and used an existing Form S-3 shelf registration and prospectus supplement for this transaction.

Outlook Therapeutics, Inc. is offering 20,000,000 shares of common stock together with warrants to purchase up to 20,000,000 shares, at a combined public offering price of $0.25 per share and accompanying warrant. The offering includes placement agent warrants to purchase 1,400,000 shares (7.0% of shares sold) exercisable at $0.3125. Delivery of securities is expected on or about March 25, 2026.

The prospectus supplement states net proceeds to the company from a full subscription would be approximately $4.0 million after placement agent fees and estimated expenses, but this is a best-efforts offering with no minimum amount required to close. The company reported 84,614,219 shares outstanding as of March 20, 2026 and discloses substantial liquidity needs, existing convertible notes, recent FDA complete response letters for ONS-5010/LYTENAVA, and regulatory and financing risks described under "Risk Factors."

Outlook Therapeutics, Inc. is offering shares of common stock, pre-funded warrants and common warrants pursuant to a preliminary prospectus supplement to a registration statement (Reg. No. 333-278340). The offering pairs each share (or pre-funded warrant) with a common warrant exercisable for one share and expiring five years after issuance.

The company reports 84,614,219 shares of common stock outstanding as of March 20, 2026 and a last reported sale price of $0.35 per share on that date. As of December 31, 2025, cash and cash equivalents were $8.7 million. Debt highlights: a $33.1 million promissory note issued March 13, 2025 (the March 2025 Note) convertible into common stock, of which Avondale converted $6.9 million into shares at a weighted average price of $0.46 as of March 20, 2026; an agreement to issue an $18.36 million note on March 16, 2026 to partially repay the March 2025 Note, leaving approximately $9.7 million remaining under the March 2025 Note as of March 20, 2026.

The company discloses three FDA Complete Response Letters regarding its BLA for ONS-5010/LYTENAVA and ongoing regulatory engagement; the FDA has indicated confirmatory evidence of efficacy is required. Outlook has EU and UK marketing authorizations and launched in initial markets. The prospectus warns of substantial doubt about Outlook’s ability to continue as a going concern and Nasdaq noncompliance with the $1.00 bid-price rule, with a compliance date of August 17, 2026.

Outlook Therapeutics entered a Note Purchase Agreement with Atlas Sciences, issuing an unsecured promissory note with an original principal balance of $18,360,000. The note was sold at a discount for $17,000,000, which must be used solely to repay $17,000,000 of an existing convertible note held by Avondale Capital.

The new note bears interest at the prime rate plus 3%, with a floor of 9.5%, matures 15 months after closing, includes a 7.5% exit fee on cash payments, and allows Atlas to redeem up to $3,000,000 per quarter starting six months after closing. After repayment, about $10.8 million remains outstanding on the Avondale note, whose maturity was extended to December 31, 2026.

In updated risk factors, the company reports cash and cash equivalents of $8.7 million as of December 31, 2025 plus $2.4 million from at-the-market sales, and states there is substantial doubt about its ability to continue as a going concern without substantial additional capital. It also highlights repeated FDA Complete Response Letters for ONS-5010/LYTENAVA and its heavy dependence on this single product.

Outlook Therapeutics, Inc. announced that its Board of Directors accepted the resignation of Dr. Julia Haller from the Board, effective March 11, 2026. She had served as a Class director and was a member of the Nominating and Corporate Governance Committee.

The Board resolved to reduce its size to nine directors upon her resignation. According to the company, Dr. Haller’s decision was not the result of any dispute or disagreement regarding the company’s operations, policies, or practices, and the Board expressed appreciation for her service.

Outlook Therapeutics, Inc. reported results of its Annual Meeting of Stockholders held on March 10, 2026. Of 73,509,455 common shares outstanding as of the record date, 37,271,431 shares, or approximately 50.70%, were present or represented by proxy, establishing a quorum.

Stockholders elected Class I directors Yezan Haddadin, Faisal G. Sukhtian and Kurt J. Hilzinger to the Board, each to serve until the 2029 Annual Meeting of Stockholders or until a successor is duly elected and qualified. This maintains continuity on the company’s Board of Directors.

Stockholders also ratified the Audit Committee’s selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, with strong support. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.

Outlook Therapeutics reported that it has held a Type A meeting with the FDA to discuss the December 30, 2025 Complete Response Letter for its Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg), an investigational treatment for wet age-related macular degeneration (wet AMD) in the United States.

The discussion focused on the FDA’s remaining concern about “substantial evidence of effectiveness” and on possible regulatory paths forward. The company plans to continue dialog with the FDA and is reviewing regulatory options to advance the program toward potential U.S. approval.

Outlook highlighted that ONS-5010 achieved clinically meaningful, statistically significant visual acuity gains in the NORSE TWO Phase 3 trial and that NORSE EIGHT and other data provide confirmatory efficacy and safety evidence, with no safety concerns identified by the FDA. The product already has Marketing Authorizations in the EU and UK and has been launched in Germany, Austria, and the UK for wet AMD, while remaining investigational in the U.S.